Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Retained Earnings (2016 - 2025)

ENDRA Life Sciences has reported Retained Earnings over the past 6 years, most recently at -$68.7 million for Q4 2021.

  • Quarterly Retained Earnings fell 19.8% to -$68.7 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$68.7 million through Dec 2021, down 19.8% year-over-year, with the annual reading at -$68.7 million for FY2021, 19.8% down from the prior year.
  • Retained Earnings was -$68.7 million for Q4 2021 at ENDRA Life Sciences, down from -$65.6 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$13.3 million in Q1 2017 and troughed at -$68.7 million in Q4 2021.
  • The 5-year median for Retained Earnings is -$34.5 million (2019), against an average of -$38.6 million.
  • Year-over-year, Retained Earnings tumbled 63.29% in 2019 and then decreased 19.06% in 2021.
  • A 5-year view of Retained Earnings shows it stood at -$17.9 million in 2017, then crashed by 54.74% to -$27.7 million in 2018, then crashed by 63.29% to -$45.2 million in 2019, then decreased by 26.81% to -$57.3 million in 2020, then dropped by 19.8% to -$68.7 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Retained Earnings are -$68.7 million (Q4 2021), -$65.6 million (Q3 2021), and -$62.9 million (Q2 2021).